Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 29 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecule offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com
AMRI and Parnell Manufacturing Pty Ltd. have entered into a development and commercial supply agreement, under which AMRI will provide process development, manufacturing and supply of APIs to support Parnell’s New Animal Drug Application (NADA) with
AMRI has received approval from the Italian Medicines Agency (AIFA) for its Burlington, MA facility to manufacture the commercial drug product octreotide for a customer in the EU.
AMRI has entered a research and licensing agreement with Roche subsidiary Genentech to develop antibacterial compounds from AMRI’s natural products sample collection.
AMRI has been selected for Pfizer’s Route Design Innovation Award, for sharing innovative ideas for process chemistry and large scale Active Pharmaceutical Ingredient (API) production.
Aquapharm Biodiscovery, a marine biotechnology company, has signed a research agreement with Albany Molecular Research (AMRI) to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s col
Dr. Hilton Klein has been named global vice president, science and new product introduction for the research models and services operating group at Harlan Laboratories.
AMRI has received certification of its high potency research labs and GMP-manufacturing facilities in Rensselaer, NY for the safe handling of potent APIs by SafeBridge Consultants, Inc.
Contract revenue for the quarter, which includes Discovery Services, Development and Small Scale Manufacturing, and Large Scale Manufacturing, was $49.6 million (+22%) and $195.5 million for the year (+20%).
Editor Gil Roth profiles the top companies in the various pharma and biopharma outsourcing arenas, with analyst perspective from investment analyst Michael Martorelli.